骨质疏松症
老化
医学
预期寿命
骨矿物
睾酮(贴片)
内科学
性类固醇
骨密度
疾病
内分泌学
生理学
类固醇
激素
人口
环境卫生
作者
Karel David,Nick Narinx,Antonio L’Abbate,Pieter Evenepoel,Frank Claessens,Brigitte Decallonne,Dirk Vanderschueren
标识
DOI:10.1007/s11154-022-09738-5
摘要
Osteoporosis does not only affect postmenopausal women, but also ageing men. The burden of disease is projected to increase with higher life expectancy both in females and males. Importantly, osteoporotic men remain more often undiagnosed and untreated compared to women. Sex steroid deficiency is associated with bone loss and increased fracture risk, and circulating sex steroid levels have been shown to be associated both with bone mineral density and fracture risk in elderly men. However, in contrast to postmenopausal osteoporosis, the contribution of relatively small decrease of circulating sex steroid concentrations in the ageing male to the development of osteoporosis and related fractures, is probably only minor. In this review we provide several clinical and preclinical arguments in favor of a 'bone threshold' for occurrence of hypogonadal osteoporosis, corresponding to a grade of sex steroid deficiency that in general will not occur in many elderly men. Testosterone replacement therapy has been shown to increase bone mineral density in men, however data in osteoporotic ageing males are scarce, and evidence on fracture risk reduction is lacking. We conclude that testosterone replacement therapy should not be used as a sole bone-specific treatment in osteoporotic elderly men.
科研通智能强力驱动
Strongly Powered by AbleSci AI